SERPING1 and hereditary angioedema: C1INH has been available in Europe for over 40 years,15 and intravenous (IV) formulations of C1INH, BERINERT® (CSL Behring, LLC) and CINRYZE® (Shire ViroPharma Biologics, Inc.)were approved in the US over a decade ago for acute treatment of HAE attacks (BERINERT) and routine prophylaxis (CINRYZE) in patients with HAE.16, 17, 18